Cell Density and Cell Aging as Factors Modulating Antifungal Resistance of Candida albicans Biofilms
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Biofilm formation is a major virulence attribute of Candida pathogenicity which contributes to higher antifungal resistance. We investigated the roles of cell density and cellular aging on the relative antifungal susceptibility of planktonic, biofilm, and biofilm-derived planktonic modes of Candida. A reference and a wild-type strain of Candida albicans were used to evaluate the MICs of caspofungin (CAS), amphotericin B (AMB), nystatin (NYT), ketoconazole (KTC), and flucytosine (5FC). Standard, NCCLS, and European Committee on Antibiotic Susceptibility Testing methods were used for planktonic MIC determination.Candida biofilms were then developed on polystyrene wells, and MICs were determined with a standard 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2 H-tetrazolium hydroxide assay. Subsequently, antifungal susceptibility testing was performed for greater inoculum concentrations and 24- and 48-h-old cultures of planktonic Candida. Furthermore,Candida biofilm-derived planktonic cells (BDPC) were also subjected to antifungal susceptibility testing. The MICs for both C.albicans strains in the planktonic mode were low, although on increasing the inoculum concentration (up to 1 × 10 8 cells/ml), a variable MIC was noted. On the contrary, for Candida biofilms, the MICs of antifungals were 15- to >1,000-fold higher. Interestingly, the MICs for BDPC were lower and were similar to those for planktonic-mode cells, particularly those of CAS and AMB. Our data indicate that higher antifungal resistance of Candida biofilms is an intrinsic feature possibly related to the biofilm architecture rather than cellular density or cellular aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms
Donlan, R. M., & Costerton, J. W. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.167-193.2002 · Cited by 6,644 · cited 1×
“These structured communities, encased in a matrix of exopolymeric substances, display unique characteristics that confer survival advantages over their planktonic counterparts (12, 14).”
BackgroundChandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578 · cited 3×
“According to the current methodology, the planktonic MIC is compared with that for 24- or 48-h biofilms (10, 16, 23, 32).”
BackgroundMethodZaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784
Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms
Ramage, G., Vande Walle, K., Wickes, B. L., & López-Ribot, J. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2475-2479.2001 · Cited by 753
Candida biofilms on implanted biomaterials: a clinically significant problem
Ramage, G., MartÃnez, J. P., & López-Ribot, J. L. (2006) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2006.00117.x · Cited by 575 · cited 1×
“), and various types of catheters (31).”
Candida albicans Biofilms Produce Antifungal-Tolerant Persister Cells
LaFleur, M. D., Kumamoto, C. A., & Lewis, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00684-06 · Cited by 521 · cited 1×
“However, it is noteworthy that some workers have shown that there is a small subpopulation of biofilm cells known as persisters with higher antifungal resistance than the rest of the biofilm population (15, 20, 22).”
BackgroundRamage, G. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf049 · Cited by 468 · cited 11×
“Next, to evaluate the possibility that the high resistance seen in Candida biofilms is a phenotypic or a genotypic feature, we performed an AST on BDPC.”
BackgroundInfluentialBiofilm lifestyle of Candida: a mini review
Seneviratne, C., Jin, L., & Samaranayake, L. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2007.01424.x · Cited by 317
Self-citationIn Vitro Activity of Caspofungin against Candida albicans Biofilms
Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3591-3596.2002 · Cited by 288
Effect of Growth Rate on Resistance of Candida albicans Biofilms to Antifungal Agents
Baillie, G. S., & Douglas, L. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.8.1900 · Cited by 234 · cited 13×
“Next, to evaluate the possibility that the high resistance seen in Candida biofilms is a phenotypic or a genotypic feature, we performed an AST on BDPC.”
BackgroundResultInfluential
Cited by
Pathogenesis of Candida albicans biofilm
Tsui, C., Kong, E. F., & Jabra-Rizk, M. A. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw018 · Cited by 481
Mechanisms of Candida Biofilm Drug Resistance
Taff, H. T., Mitchell, K. F., Edward, J. A., & Andes, D. R. (2013) · Future Microbiology · doi:10.2217/fmb.13.101 · Cited by 422
“Impact of cell density & quorum sensing Another biofilm-specific trait suspected to influence drug susceptibility is the relatively high concentration of fungal cells in a biofilm compared with many planktonic conditions [80,81].”
BackgroundOtter, J. A., Vickery, K., Walker, J. T., deLancey Pulcini, E., Stoodley, P., Goldenberg, S. D., Salkeld, J. A. G., Chewins, J., Yezli, S., & Edgeworth, J. D. (2015) · Journal of Hospital Infection · doi:10.1016/j.jhin.2014.09.008 · Cited by 263
Martins, M., Henriques, M., Lopez‐Ribot, J. L., & Oliveira, R. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02047.x · Cited by 174
Nett, J. E., Cain, M. T., Crawford, K., & Andes, D. R. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02273-10 · Cited by 153
“It is the method most commonly utilized for quantitative measurement of Candida biofilm mass, growth, and response to drug therapy (1, 9, 12, 18, 20, 26, 28, 37).”
MethodLi, P., Seneviratne, C. J., Alpi, E., Vizcaino, J. A., & Jin, L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00543-15 · Cited by 95
“These species were successfully used in our previous studies (6, 21).”
BackgroundMethodSelf-citationProteomics of drug resistance in Candida glabrata biofilms
Seneviratne, C. J., Wang, Y., Jin, L., Abiko, Y., & Samaranayake, L. P. (2010) · PROTEOMICS · doi:10.1002/pmic.200900611 · Cited by 74
“glabrata biofilms was performed using standard XTT reduction assay, as described previously [16, 19].”
MethodSelf-citationTruong, T., Zeng, G., Qingsong, L., Kwang, L. T., Tong, C., Chan, F. Y., Wang, Y., & Seneviratne, C. J. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.061523 · Cited by 45
“Biofilm Formation—Biofilm development methodology was adapted from our well-established protocol (13, 14).”
MethodSelf-citationJin, J., Guo, N., Zhang, J., Ding, Y., Tang, X., Liang, J., Li, L., Deng, X., & Yu, L. (2010) · Letters in Applied Microbiology · doi:10.1111/j.1472-765x.2010.02900.x · Cited by 40
Enhanced Efflux Pump Activity in Old Candida glabrata Cells
Bhattacharya, S., & Fries, B. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02227-17 · Cited by 19
Metadata
- Authors
- Seneviratne, C. J., Jin, L. J., Samaranayake, Y. H., & Samaranayake, L. P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-09
- Volume
- 52
- Issue
- 9
- Pages
- 3259-3266
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2076269601
- Cited by
- 109
- References
- 14
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.